Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2024-04-17 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2024-04-17 English
REGISTRATION STATEMENT
Regulatory Filings
2024-04-16 English
Notification regarding unquoted securities - MSB 6 pages 18.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted securities under an employee incentive scheme by Mesoblast Limited. It includes specifics such as security codes, issue dates, and quantities. The content is a formal notification of securities issuance rather than a financial report or earnings release. It aligns with announcements related to share issues or capital changes. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive notification of capital changes.
2024-04-15 English
Application for quotation of securities - MSB 7 pages 20.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement for the application for quotation of securities. It details the issuance and quotation of securities under an employee incentive scheme, including the number of securities, issue date, and other listing rule requirements. There is no financial performance data, management discussion, or earnings information. The document is a formal announcement related to capital changes, specifically the quotation of new shares issued under an employee incentive plan. This fits the category of Share Issue/Capital Change (SHA). The document length is over 6,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement.
2024-04-15 English
Appendix 3Y for Jane Bell 2 pages 196.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares acquired, disposed, and held before and after the change. The document is a formal notification of a director's personal share transactions. It does not contain financial statements or company performance data, nor is it a report or announcement of a report. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3613 characters, consistent with a typical director's dealing notice. Therefore, the correct classification is DIRS with high confidence.
2024-04-15 English
Notification of cessation of securities - MSB 4 pages 14.8KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation (lapse) of certain securities (options) for Mesoblast Limited. It includes specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is a formal announcement related to changes in the company's securities, specifically the cessation of certain options. It does not contain financial statements, audit information, or management discussion. It is not a report but an announcement of a securities cessation event. This fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-14 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.